Exact Mass: 411.27496020000007
Exact Mass Matches: 411.27496020000007
Found 38 metabolites which its exact mass value is equals to given mass value 411.27496020000007,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Fesoterodine
C26H37NO3 (411.27732920000005)
Fesoterodine is only found in individuals that have used or taken this drug. It is an antimuscarinic prodrug used for treating overactive bladder syndrome.Fesoterodine, once converted to its active metabolite, 5-hydroxymethyltolterodine, acts as a competitive antagonists at muscarinic receptors. This results in the inhibition of bladder contraction, decrease in detrusor pressure, and an incomplete emptying of the bladder. G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents
N-Linoleoyl Methionine
C23H41NO3S (411.28069960000005)
N-linoleoyl methionine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Linoleic acid amide of Methionine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Linoleoyl Methionine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Linoleoyl Methionine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
dysolenticin J
C26H37NO3 (411.27732920000005)
A natural product found in Dysoxylum lenticellatum.
Brachystamide C|brachystamide-C|N-isobutyl-15-(3,4-methylenedioxyphenyl)-2E,4E,13E-pentadecatrienamide
C26H37NO3 (411.27732920000005)
(2E,4E,14E)-15-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pentadeca-2,4,14-trienamide
C26H37NO3 (411.27732920000005)
(2E,4E,14E)-15-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pentadeca-2,4,14-trienamide [IIN-based on: CCMSLIB00000848860]
C26H37NO3 (411.27732920000005)
(2E,4E,14E)-15-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)pentadeca-2,4,14-trienamide [IIN-based: Match]
C26H37NO3 (411.27732920000005)
Fesoterodine
C26H37NO3 (411.27732920000005)
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D000089162 - Genitourinary Agents > D064804 - Urological Agents
NA 26:8;O
C26H37NO3 (411.27732920000005)
1-[12-(4-ethylphenyl)dodecoxy]-2-nitrobenzene
C26H37NO3 (411.27732920000005)
(4Z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline
1-ethyl-2-[5-(1-ethyl-3,3-dimethyl-1,3-dihydro-2H-indol-2-ylidene)penta-1,3-dien-1-yl]-3,3-dimethyl-3H-indolium
(2-Hydroxy-3-undecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C19H42NO6P (411.27496020000007)
2-Aminoethyl (2-hydroxy-3-tetradecoxypropyl) hydrogen phosphate
C19H42NO6P (411.27496020000007)
(3s)-6-methyl-3-[(6r)-6-[(2-methyl-4-oxohexan-3-yl)-c-hydroxycarbonimidoyl]-1,2-diazinane-1-carbonyl]heptanoic acid
C21H37N3O5 (411.27330720000003)
15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,14-trienimidic acid
C26H37NO3 (411.27732920000005)
(1s,3r,6r,7z,9e,13s,15r,16r)-13-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9,11-triene-11,15-diol
C26H37NO3 (411.27732920000005)
(2e,4e,12e)-15-(2h-1,3-benzodioxol-5-yl)-n-[(2s)-butan-2-yl]pentadeca-2,4,12-trienimidic acid
C26H37NO3 (411.27732920000005)
6-methyl-3-{6-[(2-methyl-4-oxohexan-3-yl)-c-hydroxycarbonimidoyl]-1,2-diazinane-1-carbonyl}heptanoic acid
C21H37N3O5 (411.27330720000003)
15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,13-trienimidic acid
C26H37NO3 (411.27732920000005)
3-[(1r,3as,5as,7r,9ar,9br,11as)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-hydroxypyrrol-2-one
C26H37NO3 (411.27732920000005)
(2e,4e,13e)-15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,13-trienimidic acid
C26H37NO3 (411.27732920000005)
(2e,4e,14e)-15-(2h-1,3-benzodioxol-5-yl)-n-[(2s)-butan-2-yl]pentadeca-2,4,14-trienimidic acid
C26H37NO3 (411.27732920000005)
(2e,4e,12e)-15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,12-trienimidic acid
C26H37NO3 (411.27732920000005)
(2e,4e,14e)-15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,14-trienimidic acid
C26H37NO3 (411.27732920000005)
15-hydroxy-13-methoxy-3,15-dimethyl-6-(6-methylhepta-3,5-dien-2-yl)-12-azatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadeca-7,9-dien-11-one
C26H37NO3 (411.27732920000005)
15-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)pentadeca-2,4,12-trienimidic acid
C26H37NO3 (411.27732920000005)